Redmile Group LLC Decreased Stake in Amicus Therapeutics INC (FOLD) by $3.40 Million; Shares Declined

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Corporate LogoBig Money Sentiment decreased to 1.3 in Q2 2018. It has change of 0.53, from 2018Q1’s 1.83. The ratio dropped due to FOLD positioning: 24 sold and 45 reduced. 29 funds bought positions and 61 increased positions. Investors holded 214.13 million in 2018Q1 but now own 216.23 million shares or 0.98% more. Fincl Bank Of Montreal Can reported 0% stake. Moneta Grp Invest Advsr Ltd Liability Corp reported 0% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Rothschild Asset Mgmt Incorporated reported 235,513 shs. Jane Street Gp Lc, a New York-based fund reported 40,047 shs. Sabby Mgmt Ltd Limited Liability Company holds 38,344 shs or 0.09% of its capital. Rock Springs Cap Mngmt Lp owns 1.00M shs or 0.6% of their US capital. Mckinley Capital Management Lc Delaware invested in 0% or 3,857 shs. Zurcher Kantonalbank (Zurich Cantonalbank) owns 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 11,925 shs. Proshare Ltd Liability Corp owns 104,142 shs. Metropolitan Life Ins Communication holds 0% or 61,633 shs in its capital. Wexford Capital Ltd Partnership stated it has 0.32% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Emerald Advisers Incorporated Pa invested in 0.34% or 572,520 shs. Sg Americas Limited Liability Company invested in 10,308 shs. Sei Investments Communication has 34,142 shs for 0% of their capital. Bnp Paribas Arbitrage holds 9,969 shs.

FOLD had 5 insider sales and 2 buys since May 14, 2018. This’s net activity of $5.99 million. Shares for $418,000 were sold by Do Hung. The insider MCGLYNN MARGARET G sold 10,000 shs worth $160,000. 10,000 shs were sold by Baird William D III, worth $156,292. On Monday, May 14 $70,223 worth of stock was sold by Barth Jay. 5,000 Amicus Therapeutics, Inc. (NASDAQ:FOLD) shs with value of $78,166 were sold by Andrews Kurt J..

Redmile Group Llc’s holdings in Amicus Therapeutics Inc (FOLD) is decreased by 2.11% based on its latest 2018Q2 regulatory filing with the SEC. By selling 226,926 shares Redmile Group Llc made the stock sank with 26.09%. The health care company at the end of 2018Q2 was priced at $164.19M. It’s down from 10.74M at the end of the previous reported quarter. Now it had 10.51M shares held by the hedge fund . Amicus Therapeutics Inc has $2.00 billion MC. FOLD is touching $10.59 during the last trading session, after decreased 2.13%.Amicus Therapeutics, Inc. has volume of 2.29M shares. Since November 10, 2017 FOLD has declined 10.62% and is downtrending. The stock underperformed the S&P500 by 26.24%.

About $1.27B and $2.94B US Long portfolio Redmile Group Llc operates. According to a filing the fund upped its stake in Audentes Therapeutics Inc by 920,130 shares to 2.23 million shares, valued at $85.16 million in 2018Q2. Redmile Group Llc has risen its stake in Livanova Plc and also increased its holding in Deciphera Pharmaceuticals In by 655,800 shares in the quarter, for a total of 1.48M shares.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s earnings release is anticipated by WallStreet on November, 14, as reported by RTT. EPS of $-0.27 is 34.15 % up from 2017’s $-0.41 EPS. Wall Street now sees -18.18 % EPS growth despite Amicus Therapeutics, Inc. last quarter’s EPS of $-0.33.

There’s a significant Amicus Therapeutics, Inc. (NASDAQ:FOLD) news released by Nasdaq.com. It’s an article titled: “Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates” on November 05, 2018.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Total analysts of 2 have positions in Amicus Therapeutics (NASDAQ:FOLD) as follows: 0 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 0. Since August 17, 2018 according to StockzIntelligence Inc Amicus Therapeutics has 2 analyst reports. On Friday, August 17 the stock has “Neutral” rating by Chardan Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.